Physician profile
Kendall Henry
NPI 1598361321
$2,785.16
in general payments reported to CMS, 2019-2025
30 companies · $1,668 in 2025
The $1,668 reported for 2025 was more than what 89% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $24.30 · 2022: $94.03 · 2023: $526 · 2024: $473 · 2025: $1,668.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,667.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,666.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $461.36 | 2024-2025 | Nemluvio, Aklief |
| Journey Medical Corporation | $249.84 | 2025 | Emrosi |
| Ucb, INC. | $205.74 | 2025 | Bimzelx |
| Regeneron Healthcare Solutions, INC. | $182.89 | 2025 | Dupixent |
| Incyte Corporation | $176.58 | 2025 | Opzelura |
| Arcutis Biotherapeutics, INC. | $162.07 | 2024-2025 | Zoryve |
| Amgen INC. | $127.62 | 2023-2025 | Prolia, Evenity, Otezla |
| E.R. Squibb & Sons, L.L.C. | $116.55 | 2025 | Sotyktu |
| Lilly USA, LLC | $114.97 | 2022-2024 | Mounjaro, Trulicity, Zepbound |
| Janssen Biotech, INC. | $99.78 | 2025 | Tremfya |
| Novo Nordisk INC | $99.20 | 2023-2024 | Rybelsus, Ozempic |
| Bayer Healthcare Pharmaceuticals INC. | $98.83 | 2022-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $98.37 | 2023-2024 | Jardiance |
| Exact Sciences Corporation | $75.31 | 2023-2024 | Cologuard Collection Kit |
| Sanofi Pasteur INC. | $72.07 | 2023 |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $56.60 | 2025 | Anzupgo |
| Mayne Pharma Commercial LLC | $43.20 | 2024 | |
| Abbvie INC. | $38.68 | 2023-2025 | |
| Mimedx Group, INC. | $37.46 | 2025 | |
| Novartis Pharmaceuticals Corporation | $33.55 | 2025 | |
| Becton, Dickinson and Company | $29.56 | 2022 | |
| Sun Pharmaceutical Industries INC. | $28.01 | 2025 | |
| Organon LLC | $24.50 | 2025 | Vtama |
| Biofrontera INC. | $24.30 | 2025 | |
| Biogen, INC. | $24.30 | 2021 | |
| Hologic Sales and Service, LLC | $23.38 | 2023 | Thinprep 2000 Processor, Aptima |
| Antares Pharma, INC. | $22.56 | 2023 | Tlando, Nocdurna, Xyosted |
| Alkermes, INC. | $22.35 | 2022 | |
| Averitas Pharma INC. | $17.83 | 2024 | Qutenza |
| Embecta Corp. | $17.70 | 2023 | Bd Nano 2nd Gen Pen Needle |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kendall Henry listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.